Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Control Release ; 145(2): 159-64, 2010 Jul 14.
Artigo em Inglês | MEDLINE | ID: mdl-20385182

RESUMO

For delivery of siRNA, chitosan (CS) was derivatized with poly-l-arginine (PLR) and polyethylene glycol (PEG). The formation of polyplexes with siRNA was confirmed by gel retardation. The PLR-grafted CS formed nanosized particles with siRNA. PLR-grafted CS showed higher cellular delivery efficiency of siRNA than did CS, pegylated CS, PLR, or pegylated PLR. The extent of reduction in the expression of fluorescent proteins was highest following treatment of the cells using PLR derivatives of CS in complexes with specific siRNAs. Cell viability was greater in populations treated with pegylated CS-PLR than in those treated with PLR. Hemolysis of erythrocytes was reduced upon conjugation of PLR with CS. The delivery of siRNAs via pegylated CS-PLR revealed little dependence on serum. Molecular imaging techniques revealed that the intratumoral administration of red fluorescent protein-specific siRNA in complexes with pegylated CS-PLR significantly silenced the expression of red fluorescent proteins in tumor tissues in vivo. These results indicate that pegylated CS-PLR might be useful for in vivo delivery of therapeutic siRNAs.


Assuntos
Quitosana/química , RNA Interferente Pequeno/administração & dosagem , Animais , Arginina/química , Carcinoma Hepatocelular/patologia , Carcinoma Hepatocelular/terapia , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Portadores de Fármacos , Hemólise/efeitos dos fármacos , Humanos , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/terapia , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/terapia , Camundongos , Peso Molecular , Polietilenoglicóis/química , Polímeros/química , Polímeros/farmacologia , Polímeros/toxicidade
2.
Invest Ophthalmol Vis Sci ; 51(9): 4707-15, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20375325

RESUMO

PURPOSE: The effects of small interfering (si)RNA of nuclear factor kappa B (NF-kappaB) on the development of posterior capsule opacification (PCO) were investigated both in vitro and in vivo in rabbits. METHODS: After application of p105 NF-kappaB siRNA to lens epithelial cells (LECs), Western blot analyses were performed to detect p105 and p50 NF-kappaB and a scratch assay was used to determine cell migration. In the capsular bag model, immunocytochemistry was performed to determine expression of p50 NF-kappaB and Western blot analyses for the presence of epithelial-to-mesenchymal transition (EMT) markers. Two sequences of p105 NF-kappaB siRNA were used in cataract surgery in 15 New Zealand White rabbits. PCO grading was conducted by slit lamp biomicroscopy and a computer-based PCO grading program. One month after surgery, the eyes of the rabbits were enucleated, and sections were prepared for examination of the posterior capsule and other ocular tissues by light microscopy. RESULTS: Application of p105 NF-kappaB siRNA to LECs decreased p105 NF-kappaB and p50 NF-kappaB expression, and migration of LECs was shown to be inhibited on the scratch assay. In the capsular bag model, the LEC count was significantly decreased, and immunocytochemistry showed reduced p50 NF-kappaB expression on the posterior capsule. EMT markers were significantly decreased after application of p105 NF-kappaB siRNA in the capsular bag model. In the in vivo study in rabbits, p105 NF-kappaB siRNA effectively decreased PCO, as determined by both slit lamp examination and the PCO grading program. CONCLUSIONS: NF-kappaB seems to be related to migration and proliferation of LECs. NF-kappaB siRNA was effective in inhibiting the migration and proliferation of LECs in vitro and decreased PCO formation after cataract surgery in an in vivo rabbit model.


Assuntos
Extração de Catarata , Terapia Genética/métodos , Cápsula do Cristalino/patologia , Subunidade p50 de NF-kappa B/genética , Complicações Pós-Operatórias/terapia , RNA Interferente Pequeno/farmacologia , Animais , Biomarcadores/metabolismo , Western Blotting , Divisão Celular , Movimento Celular , Modelos Animais de Doenças , Processamento de Imagem Assistida por Computador , Imuno-Histoquímica , Subunidade p50 de NF-kappa B/metabolismo , Técnicas de Cultura de Órgãos , Complicações Pós-Operatórias/patologia , Coelhos , Cicatrização
3.
Cell Transplant ; 17(10-11): 1257-69, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-19181219

RESUMO

The necessity to transplant islet tissue without the need for immunosuppressant therapy has led to the development of materials for immune modulation. Pegylation makes islets antigenically silent, protecting them from the adsorption of foreign protein and thus avoiding immune injury. The aim of this study is to determine whether pegylation of islets prolongs islet survival and function both during tissue culture and posttransplantation. We used cyanuric chloride-activated methoxy-polyethylene glycol for cell surface modification. To detect the pegylation effect on splenocytes, we measured antibody binding inhibition and abrogation of lymphocyte proliferation. To detect the pegylation effect on islet grafts, we performed rodent islet transplantation. Islet viability and function were maintained after pegylation. Pegylated islets showed a 90% decrease in antibody binding and decreased lymphocyte proliferation in a mixed lymphocyte culture. However, when pegylated islets were transplanted, no prolongation of graft survival was observed. When a subtherapeutic dose of immunosuppressant was given at the time of transplantation of pegylated islets, islet graft survival was significantly prolonged. In addition, when rats were sensitized with donor splenocytes, graft survival was prolonged by pegylation. We observed that pegylation of islets, combined with a subtherapeutic dose of immunosuppressant, protects the graft from rejection. Prolonged graft survival in sensitized recipients showed that pegylation of islets shifted the pattern of rejection from an acute humoral response to a less aggressive cellular alloresponse.


Assuntos
Antígenos de Superfície/efeitos dos fármacos , Diabetes Mellitus Experimental/terapia , Rejeição de Enxerto/prevenção & controle , Transplante das Ilhotas Pancreáticas/métodos , Polietilenoglicóis/farmacologia , Animais , Antígenos de Superfície/imunologia , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Reagentes de Ligações Cruzadas/farmacologia , Diabetes Mellitus Experimental/imunologia , Terapia de Imunossupressão/métodos , Ilhotas Pancreáticas/efeitos dos fármacos , Ilhotas Pancreáticas/imunologia , Ilhotas Pancreáticas/fisiologia , Transplante das Ilhotas Pancreáticas/imunologia , Ratos , Ratos Endogâmicos F344 , Ratos Endogâmicos Lew , Estreptozocina , Propriedades de Superfície/efeitos dos fármacos , Tolerância ao Transplante/efeitos dos fármacos , Triazinas/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...